The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper versions. After an outcry, it’s reconsidering.

The government has suggested weight-loss drugs could boost the economy by helping obese people in England get back to work. But NHS experts have warned treatment services are already overstretched trying to deal with unprecedented demand from patients wanting these drugs.

A new study suggests that medications like Ozempic could help reduce the risk of overdose and alcohol intoxication in people with substance use disorders.

Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.

What this means is that by changing only one hormone, “suddenly you change your entire relationship with food”, says Prof Giles Yeo, an obesity scientist at the University of Cambridge. And that has all sorts of implications for the way we think about obesity.

Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer greater benefits than just weight and diabetes management.

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds Ozempic, Wegovy, Mounjaro or Zepbound, may help users overcome alcoholism and opioid addiction.

Weight loss medications such as Ozempic may be able to cut drug and alcohol misuse in half, according to a new study from the scientific journal Addiction. The research, published Thursday, found that people who take Ozempic or similar drugs — those used for weight loss or treating Type 2 diabetes — were 40